Zimmer Biomet Beats Q1 Estimates and Raises Full-Year Guidance

Key Facts

Zimmer Biomet Holdings, Inc. reported robust first-quarter results, with revenue increasing 9.3% to $2.087 billion and adjusted EPS rising 15% to $2.09. Following this performance, the company raised its full-year adjusted EPS guidance to a range of $8.40 to $8.55. While management noted some account losses in the U.S. and ongoing operational changes, these were offset by significant growth in the technology and data sectors. Looking ahead, the company expects mid-single-digit international growth in the second half of the year. This update reflects management's confidence in navigating domestic headwinds through technological momentum and global expansion. Investors continue to monitor ZBH shares as the firm demonstrates strong operational health despite regional challenges.

Version History